Overview
Insulin, Neurogenetics and Memory in Alzheimer's Disease
Status:
Completed
Completed
Trial end date:
2003-03-01
2003-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
US Department of Veterans AffairsVA Office of Research and Development
Treatments:
RosiglitazoneCriteria
Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbidconditions.